Local ablation of liver and lung metastases in patients with colorectal cancer after failure of first- or later-line systemic chemotherapy – a prospective trial

Local ablation of liver and lung metastases in patients with colorectal cancer after failure of first- or later-line systemic chemotherapy – a prospective trial - LOCOMOTIVE

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00006295

Enrollment

200

Registered

2016-04-11

Start date

2014-01-22

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

C18 C19 C20

Interventions

Group 1: Patients treated within the study will receive local ablations (LA, means thermal and irradiation techniques) after failure of systemic therapy and the effect of LA in different time points (

Eligibility

Sex/Gender

All

Age

18 Years to 85 Years

Inclusion criteria

Inclusion criteria: • Histologically confirmed colorectal cancer with liver, lung and / or lymph node metastases • progression after chemotherapy • No more than 2 members with active disease • primary tumor resected, no evidence of local recurrence • diameter of the largest liver lesion max. 5 cm, not more than five liver metastases OR Diameter of the largest lesion 15cm, not more than three liver metastases (Satellite metastases near the target lesion excluded) • No more than three lung metastases with a diameter of max. 5cm OR not more than five lesions up to 3 cm diameter • No more than two distant metastases outside the lung and liver (except bone metastases) • ECOG performance status = 1 • Karnofsky Index = 70%

Exclusion criteria

Exclusion criteria: • Cerebral metastasis • Symptomatic bone metastasis • peritoneal, pleural carcinosis • Other malignant diseases • Life expectancy <6 months • violation of an inclusion criterion

Design outcomes

Primary

Measure	Time frame
Progression-free survival after local percutaneous ablation of colorectal liver and lung metastases in patients with progression under first-line (second/thrid line) chemotherapy compared to survival without progression of systemically treated patients group as part of a matched-pair analysis (diagnostic imaging, clinical data and questionnaire)	—

Secondary

Measure	Time frame
- Effectiveness/local tumor control (follow up CT and/or MRI every 3 months) - Overall survival and quality of life (EQ-5D) of patients (clinical data, questionnaire every 3 months) - these results will be associated with results from collected blood and tissue samples to identify prognostic factors (e.g. microsatellite instability, mutation status: kras/nras/braf, micro-RNA in blodd and tissue)	—

Countries

Germany

Contacts

Public ContactChristel Besseler

Klinik für Radiologie und Nuklearmedizin

christel.besseler@med.ovgu.de+49-391-6713071

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026